HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

2,4,6- trimethyl- N- ((3'- (methylsulfonyl)- 4- biphenylyl)methyl)- N- ((5- (trifluoromethyl)- 2- furanyl)methyl)benzenesulfonamide

a liver X receptor antagonist; structure in first source

Also Known As:

GSK 2033; GSK-2033; GSK2033

Networked: 3 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133

Experts

1.	Cao, Hui: 1 article (01/2019)
2.	Chen, Chuan: 1 article (01/2019)
3.	Chen, Jiulin: 1 article (01/2019)
4.	Dou, Fangfang: 1 article (01/2019)
5.	Jia, Qingling: 1 article (01/2019)
6.	Liu, Te: 1 article (01/2019)
7.	Shen, Dingzhu: 1 article (01/2019)
8.	Burris, Thomas P: 1 article (10/2016)
9.	Griffett, Kristine: 1 article (10/2016)

Related Diseases

1.	Inflammation (Inflammations) 01/01/2019 - "In this study, we first confirmed the effects of an LXRα agonist (T0901317) and antagonist (GSK2033) on foam cell formation and inflammation in vivo and in vitro. "
2.	Non-alcoholic Fatty Liver Disease 10/21/2016 - "Although GSK2033 performed as expected in cell-based models as a LXR inverse agonist, it displayed unexpected activity in the mouse NAFLD model. "
3.	Pathologic Neovascularization 11/01/2023 - "LXR inhibition (GSK2033 treatment) in Sult2b1 -/- macrophages reversed M2 polarization and decreased intracellular cholesterol capacity to promote pathological angiogenesis. "
4.	Fatty Liver 10/21/2016 - "Promiscuous activity of the LXR antagonist GSK2033 in a mouse model of fatty liver disease."

Related Drugs and Biologics

1.	T0901317
2.	Cholesterol